Drugs / COLESTILAN CHLORIDE
last change May 2015 re-read 2 minutes ago

COLESTILAN CHLORIDE

Other / unclassified

Developed for
chronic kidney disease · hyperphosphatemia · hyperlipidemia · type 2 diabetes mellitus
Investigated by
Tanabe Pharma Corporation

Regulatory milestones approvals, filings & regulatory actions · 2 recorded

MilestoneJurisdictionBrandIndicationDateSentence it was read from
Withdrawn EU (EMA) BindRen 2015-05-26 europa.eu
Approved EU (EMA) BindRen 2013-01-21 europa.eu

Trials 11 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 21 trial
Phase 2 NCT00497198 Oct 2005 → Sep 2007 type 2 diabetes mellitus Tanabe Pharma Corporation Completed No outcome recorded
Phase 310 trials
Phase 3 NCT01814904 Apr 2014 → Jan 2015 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Terminated No outcome recorded
Phase 3 NCT01814917 Aug 2013 → Dec 2014 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Terminated No outcome recorded
Phase 3 NCT01818687 Aug 2013 → Dec 2014 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Terminated No outcome recorded
Phase 3 NCT00858637 Mar 2009 → Mar 2010 chronic kidney disease Tanabe Pharma Corporation Completed No outcome recorded
Phase 3 NCT00772382 Dec 2008 → Aug 2010 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Completed No outcome recorded
Phase 3 NCT00542386 Dec 2007 → Nov 2009 chronic kidney disease, hyperlipidemia, hyperphosphatemia Tanabe Pharma Corporation Completed No outcome recorded
Phase 3 NCT00542815 Nov 2007 → Aug 2010 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Completed No outcome recorded
Phase 3 NCT00506441 Sep 2007 → Sep 2009 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Completed No outcome recorded
Phase 3 NCT00416520 Jun 2007 → Nov 2009 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Completed No outcome recorded
Phase 3 NCT00451295 May 2007 → Jan 2011 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Terminated No outcome recorded
Also used as a comparator or background therapy in 2 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT01976572 Comparator Oct 2013 → Jan 2014 chronic kidney disease, hyperphosphatemia Tanabe Pharma Corporation Completed No outcome recorded
Phase not applicable1 trial
NCT00548145 Comparator Nov 2007 → Oct 2011 Alzheimer disease, hyperlipidemia Osaka University Terminated No outcome recorded

Evidence & citations 11 cited values

Every value below carries the sentence it was read from. 15 sources stand behind the page.

FieldValueCited text
Known as COLESTILAN CHLORIDE ChEMBL registry synonym — accepted as the source's own label CHEMBL2103800
Known as Bindren ChEMBL registry synonym — accepted as the source's own label CHEMBL2103800
Known as CHOLEBINE “MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)” NCT00416520
1

“MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)” NCT00451295

Known as Cholebine (japan) ChEMBL registry synonym — accepted as the source's own label CHEMBL2103800
Known as Colestilan “MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)” NCT00416520
4

NCT01814904

NCT01814917

NCT01976572

NCT01818687

Known as colestilan(INN) “MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)” NCT00451295
Known as Colestimide “MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)” NCT00416520
1

NCT00548145

Known as Colestimide(JAN) “MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)” NCT00451295
Known as MCI-196 “The objective of this study is to assess the safety and tolerability of colestilan (MCI-196) in paediatric subjects (aged 2 years to \<18 years) with CKD stages 3b to 5,...” NCT01818687
9

“treatment with colestilan (MCI-196)” NCT01814917

NCT00416520

NCT00497198

NCT00506441

NCT00772382

NCT00451295

NCT00858637

NCT00542815

NCT00542386

Modality Other / unclassified “a bile acid sequestrant” PMID 20047620 Sep 2009
Route Oral “Colestilan was administered orally 5 g t.i.d” NCT01976572